June 11, 2020 by Chain Drug Review
Chip Davis, COVID-19, HDA, supply chain
Leading Headlines, Pharmacy
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) released policy principles reaffirming the pharmaceutical distribution industry’s commitment to assisting the country and frontline healthcare providers during pandemics and public health emergencies. HDA highlights four priority areas: Supply Chain Coordination: Coordination between the public and private sector is key to addressing public health crises. Accordingly, a consolidated contact within the
June 2, 2020 by Brian Bossetta
Chip Davis, COVID-19, HDA, HDA (formerly known as the Healthcare Distribution Management Association)
Leading Headlines, News, Pharmacy, Supplier News
ARLINGTON, Va. — Taking on a new leadership role is never easy; taking the helm during a global pandemic, however, especially when job No. 1 for the organization’s members involves keeping the country’s vital medical supply chain running smoothly, defines daunting. But being named president and chief executive officer of the Healthcare Distribution Alliance
May 20, 2020 by Chain Drug Review
Chip Davis, COVID-19, HDA
Leading Headlines, Pharmacy, Supplier News
ARLINGTON, Va. — HDA has released a two-minute video that further reinforces the pharmaceutical distribution industry’s critical function as it adapts and rises to the challenge of COVID-19, while also continuing the vital work of delivering the medicines Americans rely on to manage their daily health care needs. The video features HDA president and CEO
April 28, 2020 by Chain Drug Review
Chip Davis, COVID-19, HDA (formerly known as the Healthcare Distribution Management Association)
Leading Headlines, Pharmacy
ARLINGTON, Va.— On April 27, HDA president and CEO Chester “Chip” Davis, sent a letter to the leadership of major pharmacy organizations to underscore how individual distributors typically manage, and are adapting to, the unprecedented supply challenges presented by COVID-19. Recipients included: American Association of Colleges of Pharmacy; American Pharmacists Association; American Society of Health-System Pharmacists;
April 17, 2020 by Chip Davis
Chip Davis, COVID-19, HDA
Opinion
Across the country, brave, frontline health care professionals are working around the clock as our nation grapples with the COVID-19 pandemic. These workers — the true heroes of the pandemic — are treating patients, maintaining vital health care operations and serving as emergency responders. In this time of crisis, it is also important to remember
March 9, 2020 by Chain Drug Review
Chip Davis, Healthcare Distribution Alliance (HDA)
Leading Headlines
ARLINGTON, Va. – In response to the Food and Drug Administration’s (FDA) proposed rule on prescription drug importation, Healthcare Distribution Alliance (HDA) president and CEO Chester “Chip” Davis, Jr. released the following statement: “As the vital link within the healthcare ecosystem, HDA’s pharmaceutical distributor members share FDA’s commitment to ensuring that Americans have access to
February 10, 2020 by Chain Drug Review
Chip Davis, Greg Drew, HDA, John Gray, The Healthcare Distribution Alliance (HDA) board of directors’ executive committee
Leading Headlines, Pharmacy
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) board of directors’ executive committee announced Monday the appointment of Chester “Chip” Davis, to the position of president and chief executive officer. Davis will join HDA during March of this year. He joins HDA coming from the Association for Accessible Medicines (AAM), the nation’s leading trade association
January 10, 2020 by Chip Davis
Association for Accessible Medicines, Chip Davis
Issue 01-06-2020, Opinion
The public continues to name health care costs — and prescription drugs in particular — as a top priority. A recent survey from the Kaiser Family Foundation found that eight in 10 Americans say the cost of prescription drugs is unreasonable. At the same time, the value of generic medicines is well established. Consider this:
January 22, 2019 by Chip Davis
Association for Accessible Medicines, Chip Davis
Featured Articles, Issue 01-07-2019, Leading Headlines, Pharmacy
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the
June 12, 2017 by Geoff Walden and Chain Drug Review
2017 AAM Generic Drug Access & Savings in the U.S., AAM, Association for Accessible Medicines, Chip Davis, generic drugs, Prescription abandonment
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics
June 9, 2017 by CDR Blog and Chain Drug Review
AAM, Alex Brill, Association for Accessible Medicines, Chip Davis, Matrix Global Advisors, new generic drugs, Pharmaceutical Research and Manufacturers of America, PhRMA, REMS, REMS and Restricted Distribution Programs, Risk Evaluation Mitigation Strategies
CDR Blog
The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and
February 14, 2017 by Chain Drug Review
AAM, Apotex, Association for Accessible Medicines, biosimilars, Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA, GPhA Annual Meeting, Heather Bresch, Jeff Watson, Lupin Pharmaceuticals, mylan, Paul McGarty, Peter Goldschmidt, Sandoz
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly
October 19, 2016 by Chain Drug Review
Chip Davis, generic drugs, Generic Pharmaceutical Association, generic prescription drugs, GPhA, GPhA's 2016 Generic Drug Savings and Access in the United States report, health care spending, QuintilesIMS Institute, U.S. drug spending
Leading Headlines, Pharmacy, Retail News
WASHINGTON — Annual health care savings from generic prescription drugs rose nearly 10% last year to $227 billion, according to the Generic Pharmaceutical Association (GPhA). GPhA’s 2016 Generic Drug Savings and Access in the United States report, released Wednesday, tallied the 10-year national savings for generics at $1.46 trillion, representing a gain of 328% from
May 20, 2016 by Chain Drug Review
Chip Davis, EAR, Expedited Agency Review, FDA, Food and Drug Administration, generic drug labeling, generic drug manufacturers, generic drugs, Generic Pharmaceutical Association, GPhA
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The Food and Drug Administration is again postponing the release of a final rule that would change generic drug labeling requirements. In a Federal Register notice this week, the FDA indicated that it aims to implement the final rule in April 2017, though many industry stakeholders had expected the agency to do so
